证券代码：688621 证券简称：阳光诺和 公告编号：2023-020 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 03 月 23 日上午 10:00-11:00 会议召开时间：2023 年 03 月 23 日(星期四)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 16 日(星期四)至 03 月 22 日(星期三)16:00 前登录 上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 ir@sun-novo.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 北京阳光诺和药物研究股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...

Financial Performance - In 2022, the company achieved operating revenue of 676.61 million yuan and a net profit attributable to shareholders of 155.95 million yuan, with earnings per share of 1.95 yuan[4]. - The company reported a total revenue of RMB 500 million for the fiscal year 2022, representing a year-over-year increase of 25%[22]. - The company achieved operating revenue of 676.64 million yuan in 2022, representing a year-on-year growth of 37.06%[44]. - Net profit attributable to shareholders reached CNY 155.95 million, up 47.59% compared to the previous year[32]. - The net profit after deducting non-recurring gains and losses was CNY 141.63 million, reflecting a growth of 38.69% year-on-year[32]. - The net cash flow from operating activities increased by 17.80% to CNY 103.96 million[32]. - The company's total assets at the end of 2022 were CNY 1,463.09 million, a 17.74% increase from the previous year[33]. - The net assets attributable to shareholders grew by 17.68% to CNY 896.70 million[33]. - The company reported a total revenue of 4,391,429.00, with a net profit of 534,178.16, indicating a strong financial performance[93]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% growth compared to the previous year[182]. Research and Development - Research and development investment totaled 89.69 million yuan, accounting for 13.26% of revenue, with a research team of 951 personnel, representing 84.46% of the workforce[7]. - The proportion of R&D investment to operating revenue increased by 3.62 percentage points to 13.26%[31]. - The company has invested RMB 50 million in new technology for drug formulation, aiming to improve production efficiency by 25%[22]. - The company reported a total R&D expenditure of ¥89,685,673.07, an increase of 88.51% compared to the previous year, driven by investments in innovative drugs and improved generic drugs[72]. - The company is focusing on the development of innovative drugs, particularly in the areas of peptide and small nucleic acid drugs, with all research projects being self-initiated[49]. - The company is enhancing its capabilities in innovative drug services, focusing on peptide-based drugs and advanced drug design technologies[2]. - The company is actively pursuing new technology development to enhance the efficiency of its manufacturing processes[92]. Market Expansion and Strategy - The company plans to distribute a cash dividend of 6.00 yuan per 10 shares, totaling 48 million yuan, which represents 30.78% of the net profit attributable to shareholders[11]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by the end of 2024[22]. - The company is exploring market expansion opportunities in the field of chemical generic drugs, particularly in the treatment of hypertension[84]. - The company is actively pursuing the registration of multiple new products, with several in the trial phase, indicating ongoing innovation[96]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[182]. - The company aims to expand its business by acquiring 100% equity of Langyan Life Science, which specializes in high-end chemical drug formulation and raw material production[165]. Product Development and Pipeline - Eight new drug projects received NMPA approval for clinical trials, with 60 drug applications accepted for market registration and 24 for consistency evaluation[5]. - The company has received approval for 26 drug production registration certificates and 15 consistency evaluations[5]. - New product development includes the launch of two innovative drugs, expected to enter the market in Q3 2023, with projected sales of RMB 100 million each in the first year[22]. - Clinical trials for three new drugs are currently underway, with expected completion by Q4 2023[22]. - The company has successfully initiated 8 new drug projects that have received NMPA approval for clinical trials, along with 60 drug registration applications accepted[70]. Operational Efficiency - The overall operational cost has been reduced by 10% due to improved supply chain management[22]. - The average output per employee reached CNY 600,900, an increase of CNY 35,400 compared to the previous year[32]. - The company has implemented a new marketing strategy focusing on digital channels, aiming to increase customer engagement by 40%[22]. - The company has established a comprehensive "preclinical + clinical" drug development service model, improving the probability of successful drug development[100]. Risk Management - The company has outlined potential risks in its annual report, emphasizing the importance of risk awareness for investors[9]. - The company faces risks related to technological upgrades and potential drug development failures, which could impact future profitability[105]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring clear responsibilities and effective operation among its governing bodies[172]. - The company maintained a stable management team with no significant changes in shareholding for key executives during the reporting period[179]. - The company’s board of directors is responsible for submitting the remuneration plans to the shareholders' meeting for approval[193]. Human Resources - The company employs 1,126 staff, with 951 in R&D, representing 84.46% of total employees[60]. - Total compensation for R&D personnel reached 140,189,477.04 RMB, with an average salary of 168,294.69 RMB, compared to 154,338.83 RMB in the previous year[99]. - The average age of R&D personnel shows a youthful demographic, with 657 individuals under 30 years old, which may contribute to innovative approaches[99]. Financial Management - The company reported a significant decrease in financing cash flow, down 95.39% to ¥26,219,083.13, compared to the previous year[133]. - Accounts receivable increased by 85.19% to CNY 202,697,666.92, driven by revenue growth, although collection was slower due to the pandemic[136]. - The company’s financial assets decreased by 91.68% to CNY 13,107,081.60, primarily due to the maturity of purchased financial products[136].

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 （2022 年 5 月） | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n□新闻发布会 □路演活动 \n 现场参观 \n□其他（电话会议） | 分析师会议 \n 业绩说明会 | | 参与单位名称 同花顺 | | | | 时间 2022 | 年 5 月 31 日 | | | 参会方式 | 媒体采访录制 | | | 上市公司接待人 员姓名 | 董事、总经理：刘宇晶先生 | | | | 1. | 公司未来的核心业务增长点是什么？ | | | | 回复："仿创结合，一站式服务"是公司发展的主 | | | | 要方向，基于这个 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥170,931,848.01, representing a year-over-year increase of 46.12%[10] - Net profit attributable to shareholders for Q3 2022 was ¥41,522,105.64, up 58.68% compared to the same period last year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥38,806,994.17, reflecting a 48.33% increase year-over-year[10] - Basic earnings per share for Q3 2022 were ¥0.52, up 57.58% year-over-year[12] - Total revenue for the first three quarters of 2022 reached ¥495,240,315.22, a significant increase from ¥341,097,584.39 in the same period of 2021, representing an increase of approximately 45.2%[40] - Operating profit for the first three quarters of 2022 was ¥138,459,567.13, up from ¥99,819,540.64 in 2021, reflecting a growth of approximately 38.7%[43] - The total profit for the period reached ¥138,280,701.76, an increase from ¥99,589,235.79 in the previous year, representing a growth of approximately 38.8%[47] - Net profit attributable to shareholders of the parent company was ¥128,904,629.15, up from ¥85,132,224.00, marking a year-over-year increase of about 51.4%[49] - Basic and diluted earnings per share were both ¥1.61, compared to ¥1.42 in the same period last year, reflecting an increase of 13.4%[49] Research and Development - R&D investment totaled ¥20,570,732.16 in Q3 2022, accounting for 12.03% of revenue, a decrease of 1.56 percentage points from the previous year[12] - R&D investment for the year-to-date reached ¥56,698,742.50, reflecting a 58.92% increase compared to the previous year[12] - The company has invested significantly in R&D, with R&D expenses reaching ¥56,698,742.50, up from ¥35,676,542.07, indicating a focus on innovation and product development[43] Assets and Liabilities - The total assets of the company at the end of Q3 2022 were ¥1,361,723,218.02, an increase of 9.58% compared to the end of the previous year[12] - Non-current assets totaled ¥383,753,884.31, an increase from ¥300,865,652.43 year-over-year, marking a growth of about 27.5%[40] - Total assets amounted to ¥1,361,723,218.02, compared to ¥1,242,650,859.02 in the previous year, representing an increase of approximately 9.6%[40] - Current liabilities increased to ¥440,028,970.00 from ¥417,825,548.02, showing a rise of about 5.0%[40] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥8,031,810.43 for the year-to-date, a significant decrease of 82.38% compared to the previous year[12] - Cash flow from operating activities amounted to ¥8,031,810.43, a decrease from ¥45,583,455.19 in the previous year[52] - Cash and cash equivalents at the end of the period totaled ¥559,003,256.01, compared to ¥271,282,400.47 at the end of the same period last year, indicating a significant increase of 106.6%[53] - The company's cash and cash equivalents as of September 30, 2022, amount to ¥559,003,256.01, an increase from ¥490,251,185.19 at the end of 2021[35] - The company reported cash inflow from investment activities of ¥137,226,019.65, compared to ¥809,869.59 in the previous year, showing a substantial increase[52] - The company recorded cash outflow from financing activities of ¥111,620,050.83, compared to ¥31,421,781.69 in the previous year, indicating increased financing activities[52] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,004, with the largest shareholder holding 27.59% of shares[24] - Liu Yujing, a natural person, holds 4,333,701 shares, representing 5.42% of the total shares, with 2,000,000 shares pledged[24] - The top ten shareholders hold a significant portion of the company's shares, with the top three alone accounting for over 36%[24] - The total number of shares held by the top ten unrestricted shareholders is 16,000,000, indicating a concentrated ownership structure[28] Strategic Outlook - The company attributed the revenue growth to strengthened market expansion and the operational efficiency improvements from new laboratory setups[18] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[48]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a total revenue of CNY 500 million, representing a 25% year-over-year growth[1]. - The company reported a revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[14]. - The company achieved operating revenue of RMB 324.31 million in the first half of 2022, representing a year-on-year increase of 44.71%[20]. - Net profit attributable to shareholders reached RMB 87.38 million, up 48.19% compared to the same period last year[22]. - The company reported a total revenue of approximately ¥623.94 million for the first half of 2022, with a year-on-year increase of 114.69%[67]. - The company signed new orders worth RMB 545 million in the first half of 2022, reflecting a year-on-year growth of 24.15%[20]. - The company’s overall gross margin stood at 58.37%, indicating a relatively high level[90]. User Growth and Market Expansion - User data showed an increase in active users, reaching 1.2 million, which is a 15% increase compared to the previous period[1]. - User data indicates a growth in active users by 15% compared to the previous period, reaching a total of 1.5 million active users[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[14]. Research and Development - New product development is underway, with three new drug candidates expected to enter clinical trials by the end of 2022[1]. - The company has allocated CNY 100 million for research and development in 2022, a 20% increase from the previous year[1]. - The company has increased its R&D budget by 15% for 2022, totaling RMB 30 million, to support new technology initiatives[14]. - The R&D investment as a percentage of operating revenue rose to 11.14%, an increase of 2.32 percentage points compared to the previous year[21]. - The company continues to enhance its drug R&D capabilities and expand its domestic business network to support sustained growth[20]. - The company has established a comprehensive service technology platform that integrates compound synthesis, activity screening, pharmaceutical research, pharmacodynamics evaluation, pharmacokinetics, clinical trials, and bioanalysis[46]. - The company has developed a method to detect neutralizing antibodies against RSV (Respiratory Syncytial Virus) in human blood to support clinical research[14]. - The company is focusing on the development of complex formulations and special delivery methods, which are considered high-difficulty R&D areas[72]. Product Development and Innovation - New product development includes the launch of two innovative drugs, with expected market entry by Q4 2022[14]. - Clinical trials for three new drugs are currently underway, with expected completion by mid-2023[14]. - The company is focusing on improving its drug consistency evaluation process, aiming for a 30% reduction in time for product approval[14]. - The company has established advanced analysis platforms, including mass spectrometry and immunoassay platforms, to support drug development[48]. - The company is developing a modified release formulation for NKH0209 to improve stability and extend the drug's action time[57]. - The company is addressing significant technical challenges in drug formulation and stability to ensure market competitiveness[56]. Financial Management and Investments - The company has committed to managing raised funds effectively to ensure they are used for designated projects, enhancing operational efficiency and reducing costs[142]. - The company plans to accelerate the implementation of investment projects funded by the raised capital to achieve expected returns quickly[142]. - The total amount used for stock repurchase in a single fiscal year will not exceed 50% of the previous year's net profit attributable to ordinary shareholders[135]. - The company has made an investment of 20 million yuan in HaiRong Pharmaceutical through a private placement of shares[101]. - The company will ensure that all shareholder information is accurately disclosed in the prospectus[155]. Compliance and Governance - The management highlighted the importance of regulatory compliance and risk management in their operations, with a dedicated team established for this purpose[1]. - The company has established strict standard operating procedures to ensure the quality and reliability of drug research services, enhancing its core competitiveness[73]. - The company has committed to reducing carbon emissions, although specific measures and effects were not disclosed[118]. - The company has established a comprehensive environmental management system, including procedures for environmental control and waste management[117]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[116]. Shareholder and Stock Management - The company has a commitment to long-term shareholding, indicating confidence in its industry prospects[129]. - The company will comply with any additional lock-up requirements imposed by regulatory authorities[128]. - The company has established a robust investor return mechanism to ensure long-term returns for shareholders[144]. - The company will publicly apologize if it fails to establish specific stock price stabilization measures within 10 trading days after triggering conditions[138]. - The company has a three-year plan for stock price stabilization measures that automatically takes effect after the IPO[139].

Financial Performance - The company's operating revenue for Q1 2022 was ¥147,959,681.03, representing a year-on-year increase of 54.49%[9] - The net profit attributable to shareholders was ¥33,400,168.75, reflecting a growth of 62.65% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,177,429.52, up by 54.97% year-on-year[9] - The basic earnings per share for the period was ¥0.42, an increase of 23.53% year-on-year[9] - The company reported a net profit of RMB 204,697,789.95 for the period, compared to RMB 171,297,621.20 in the previous year, indicating a year-over-year increase of approximately 19.5%[29] - The total profit for Q1 2022 was ¥38,673,842.37, compared to ¥24,741,873.25 in Q1 2021, reflecting a growth of 56.2%[34] Research and Development - The total R&D investment amounted to ¥16,792,661.77, which is an increase of 73.91% compared to the previous year[10] - R&D investment accounted for 11.35% of operating revenue, an increase of 1.27 percentage points year-on-year[10] - Research and development expenses for Q1 2022 amounted to ¥16,792,661.77, up 74.5% from ¥9,655,946.39 in Q1 2021[33] Cash Flow and Liquidity - The net cash flow from operating activities was ¥3,346,533.07, down by 41.51% year-on-year, primarily due to increased employee salaries and R&D outsourcing costs[14] - Cash inflow from operating activities in Q1 2022 totaled ¥120,674,024.00, an increase from ¥88,990,608.82 in Q1 2021[36] - The net cash flow from operating activities was $3,346,533.07, a decrease of 41.5% compared to $5,721,707.67 in the previous period[39] - The ending balance of cash and cash equivalents was $581,529,765.69, up from $490,251,185.19, indicating a growth of 18.6%[40] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,286,823,731.75, a 3.55% increase from the end of the previous year[10] - The equity attributable to shareholders at the end of the reporting period was ¥795,348,786.61, up by 4.38% from the previous year[10] - The company's total current assets amounted to RMB 959,779,764.53, an increase from RMB 941,785,206.59 as of December 31, 2021, reflecting a growth of approximately 1.05%[25] - The company's total liabilities amounted to RMB 482,343,312.09, slightly up from RMB 473,009,030.17, reflecting a growth of approximately 1.41%[29] - The total equity attributable to shareholders increased to RMB 795,348,786.61 from RMB 761,948,617.86, showing a growth of about 4.39%[29] Operational Costs - Total operating costs for Q1 2022 were ¥107,867,919.54, up 56.9% from ¥68,668,959.30 in Q1 2021[33] - Sales expenses in Q1 2022 were ¥5,262,552.87, an increase of 51.1% compared to ¥3,479,107.28 in Q1 2021[33] - Management expenses for Q1 2022 reached ¥20,031,279.31, up 71.5% from ¥11,703,407.30 in Q1 2021[33] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[29]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2021, representing a year-over-year growth of 25%[21]. - The company achieved operating revenue of RMB 493.65 million in 2021, a year-on-year increase of 42.12%[30]. - Net profit attributable to shareholders reached RMB 105.66 million, up 45.81% compared to the previous year[30]. - The net cash flow from operating activities was RMB 88.25 million, reflecting a growth of 40.09% year-on-year[30]. - The company signed new orders worth RMB 929 million in 2021, representing a 76.42% increase from the previous year[30]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[21]. - The net profit margin was 22.04%, an increase of 0.69 percentage points compared to the previous year[46]. - The comprehensive gross margin for the reporting period was 53.41%, indicating a relatively high level[141]. Research and Development - The R&D investment for new products and technologies increased by 15%, totaling RMB 300 million in 2021[21]. - The company invested 9.64% of its operating revenue in R&D, slightly down from 9.84% in the previous year[30]. - The average output value per R&D personnel reached 565,500 RMB, an increase of 53,200 RMB compared to the previous year[46]. - The company has initiated 5 new drug IND applications, with 3 already obtaining clinical approval[47]. - The company has established advanced analysis platforms, including mass spectrometry and immunoassay platforms, to support pharmacokinetics and biomarker studies[71]. - The company is focusing on the development of innovative drugs, particularly peptide and small nucleic acid drugs, with all research projects being self-initiated[52]. - The company has a total of 873 employees, with 716 in R&D, accounting for 82.02% of the total workforce[48]. Market Expansion and Strategy - The company announced plans for market expansion into Southeast Asia, targeting a 10% market share within the next two years[21]. - A strategic acquisition of a local competitor was completed, valued at RMB 500 million, expected to enhance market presence and operational capabilities[21]. - The company is actively pursuing market expansion strategies and exploring potential mergers and acquisitions to enhance its product portfolio[39]. - The company collaborates with early-stage innovative drug R&D teams to enhance service offerings in pharmacokinetics and biomarker detection[52]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[11]. - The company does not have any special arrangements for corporate governance[8]. - The audit report issued by Da Hua Certified Public Accountants is a standard unqualified opinion[6]. Risks and Challenges - The company faces risks related to the rapid technological updates in the CRO industry, which may impact its future profitability and sustainable development[137]. - There is a risk of core technical talent loss and leakage, which could adversely affect the company's competitiveness and profitability[138]. - The long project cycles in the pharmaceutical research industry, typically ranging from 3 to 5 years, pose execution risks that may affect expected revenues[141]. - Future declines in pharmaceutical R&D investments due to macroeconomic conditions could negatively impact the demand for CRO services and the company's operational performance[145]. Product Development and Innovation - The company is focusing on strict quality control measures in the production of complex formulations, such as the combination of Valsartan and Amlodipine, due to the instability of raw materials[2]. - The company is actively pursuing new product development, with ongoing clinical trials for several formulations, including the Indobufen and the dual vinegar capsule[2]. - The company has developed a drug delivery system for small nucleic acid drugs, entering the small nucleic acid drug development field[71]. - The company has completed the technology transfer for multiple products, including the Indobufen and the dual vinegar capsule, indicating ongoing product development and regulatory compliance[2]. Financial Position and Assets - The company’s accounts receivable increased by 112.78% to CNY 109,454,952.74, driven by rapid revenue growth[183]. - The company’s total assets included CNY 157,600,000.00 in trading financial assets, primarily from purchasing cash management products[183]. - The cash and cash equivalents at the end of the period reached CNY 490,251,185.19, a 348.52% increase from CNY 109,305,218.92[183]. - Short-term borrowings surged to ¥138,005,000.00, a 487.26% increase from ¥23,500,000.00, mainly due to increased bank loans[189].

Financial Performance - The company's revenue for Q3 2021 reached ¥116,982,844.81, representing a 48.40% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2021 was ¥26,167,007.78, a significant increase of 158.41% compared to the same period last year[5] - The basic and diluted earnings per share for Q3 2021 were both ¥0.33, reflecting a 94.12% increase year-over-year[9] - Total revenue for Q3 2021 reached ¥341,097,584.39, a 45.4% increase from ¥234,530,370.00 in Q3 2020[39] - Net profit for Q3 2021 was ¥86,949,842.52, compared to ¥51,885,173.34 in Q3 2020, representing a 67.6% increase[41] - Total comprehensive income attributable to the parent company reached ¥85,132,224.00, up from ¥50,975,084.04 in the previous year, representing an increase of 67.5%[43] - Basic and diluted earnings per share increased to ¥1.28 from ¥0.85, reflecting a growth of 50.6%[43] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥1,016,403,557.08, marking a 164.10% increase compared to the end of the previous year[9] - The company's total assets increased to ¥1,016,403,557.08 from ¥384,855,194.54 year-over-year[35] - Non-current liabilities totaled ¥22,785,923.54, with total liabilities amounting to ¥268,603,910.72, up from ¥191,936,883.15[35] - The company's equity attributable to shareholders increased to ¥741,418,402.25, a 292.07% rise compared to the end of the previous year[9] - The total equity attributable to shareholders was approximately $189.10 million[59] - The company has a contract liability of approximately $128.29 million, indicating future revenue obligations[56] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥45,583,455.19, showing a slight decrease of 3.83% year-over-year[5] - Cash inflow from operating activities was ¥306,782,145.65, compared to ¥239,500,900.54 in the same period last year, marking an increase of 28.1%[48] - Cash outflow from operating activities totaled ¥261,198,690.46, up from ¥192,101,184.75, indicating a rise of 36.0%[48] - Net cash flow from operating activities decreased to ¥45,583,455.19 from ¥47,399,715.79, a decline of 3.8%[48] - Cash inflow from investment activities was ¥809,869.59, down from ¥6,002,136.99, a decrease of 86.5%[51] - Cash outflow from investment activities increased significantly to ¥350,925,853.99 from ¥66,052,490.99, an increase of 431.5%[51] - Net cash flow from financing activities was ¥466,509,710.76, compared to a net outflow of -¥2,785,689.40 in the previous year[51] - The ending cash and cash equivalents balance rose to ¥271,282,400.47 from ¥61,053,128.33, an increase of 344.5%[51] Research and Development - The company's R&D investment for Q3 2021 totaled ¥15,901,438.13, which is a 121.01% increase year-over-year[9] - The proportion of R&D investment to revenue for Q3 2021 was 13.59%, an increase of 4.47 percentage points compared to the same period last year[9] - Research and development expenses for Q3 2021 were ¥35,676,542.07, significantly higher than ¥19,935,145.21 in Q3 2020, indicating a 78.9% increase[39] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,924, with the largest shareholder holding 27.59% of shares[18] - The top ten shareholders hold a combined total of 56.74% of the shares, indicating a concentrated ownership structure[18] - The total number of shareholders with unrestricted shares is not specified, but the top ten unrestricted shareholders hold significant stakes[22] Inventory and Receivables - Accounts receivable rose to ¥97,179,635.99 from ¥51,440,283.55 year-over-year, indicating an increase of 88.8%[30] - The company reported an increase in inventory to ¥7,039,547.75 from ¥6,288,679.17, which is a rise of 11.9%[30] - The company has a total of ¥80,686,181.19 in contract assets, up from ¥59,524,771.50, marking an increase of 35.5%[30] Future Outlook - The increase in revenue and net profit is primarily attributed to the growth in business orders and the expansion of the technical team[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[39] - The company has not disclosed any significant new product developments or market expansion strategies in the current report[26]

Revenue and Profit - Revenue for Q3 2021 reached ¥116,982,844.81, an increase of 48.40% year-over-year[5] - Net profit attributable to shareholders for Q3 2021 was ¥26,167,007.78, up 158.41% compared to the same period last year[5] - Basic and diluted earnings per share for Q3 2021 were both ¥0.33, reflecting a 94.12% increase year-over-year[9] - Net profit for the third quarter of 2021 was ¥86,949,842.52, representing a 67.7% increase from ¥51,885,173.34 in the same quarter of 2020[39] - Total operating revenue for the first three quarters of 2021 reached ¥341,097,584.39, an increase of 45.3% compared to ¥234,530,370.00 in the same period of 2020[37] - The net profit attributable to shareholders for the year-to-date reached ¥85,132,224.00, an increase of 67.01% year-over-year[5] - The total comprehensive income for the third quarter of 2021 was ¥86,949,842.52, up from ¥51,885,173.34 in the same quarter of 2020[41] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥1,016,403,557.08, representing a 164.10% increase from the end of the previous year[9] - The company's total assets as of September 30, 2021, were ¥1,016,403,557.08, compared to ¥384,855,194.54 at the end of 2020, marking an increase of about 164.5%[31] - The total liabilities increased to ¥245,817,987.18 from ¥191,936,883.15, which is an increase of approximately 28.0%[30] - The total liabilities amounted to ¥268,603,910.72, compared to ¥191,936,883.15 in the previous year, indicating a growth of 39.8%[37] - Total liabilities amounted to 219,461,423.08, an increase of 27,524,539.93 compared to the previous period[54] - Current liabilities totaled 191,936,883.15, with accounts payable at 13,628,176.02 and contract liabilities at 128,292,304.80[54] Research and Development - R&D expenses for Q3 2021 totaled ¥15,901,438.13, a 121.01% increase compared to the same period last year[9] - The proportion of R&D expenses to revenue was 13.59%, an increase of 4.47 percentage points year-over-year[9] - Research and development expenses for the first three quarters of 2021 totaled ¥35,676,542.07, an increase of 78.9% from ¥19,935,145.21 in the previous year[37] Cash Flow - Net cash flow from operating activities for the year-to-date was ¥45,583,455.19, showing a decrease of 3.83% compared to the previous year[5] - Operating cash inflow for the first three quarters of 2021 was CNY 306,782,145.65, an increase of 28.1% compared to CNY 239,500,900.54 in the same period of 2020[46] - Cash outflow from operating activities totaled CNY 261,198,690.46, up 36.0% from CNY 192,101,184.75 year-over-year[46] - Net cash flow from operating activities decreased to CNY 45,583,455.19, down 3.8% from CNY 47,399,715.79 in the previous year[46] - Cash inflow from investment activities was CNY 809,869.59, significantly lower than CNY 6,002,136.99 in the same period last year[49] - Cash outflow from investment activities surged to CNY 350,925,853.99, compared to CNY 66,052,490.99 in the previous year[49] - Net cash flow from financing activities was CNY 466,509,710.76, a substantial increase from a net outflow of CNY 2,785,689.40 in the same period last year[49] Shareholder Information - Shareholders' equity attributable to the company was ¥741,418,402.25, a significant increase of 292.07% from the previous year[9] - The top ten shareholders hold a combined 55.74% of the total shares, with the largest shareholder owning 27.59%[18] - Owner's equity attributable to shareholders reached 189,104,685.80, with undistributed profits of 73,107,477.20[57] Other Financial Information - The company reported a financial expense of ¥1,212,540.52 for the first three quarters of 2021, which is an increase from ¥830,809.45 in the same period of 2020[37] - The company’s investment income for the first three quarters of 2021 was ¥567,205.55, compared to ¥2,136.99 in the previous year[37] - The company implemented new leasing standards starting January 1, 2021, affecting the financial statements[57] - The company has no pledged, marked, or frozen shares as of the reporting date[18] - The company has a long-term equity investment valued at ¥40,000,000.00 as of September 30, 2021[28]

Financial Performance - The company's revenue for Q3 2021 reached ¥116,982,844.81, representing a 48.40% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2021 was ¥26,167,007.78, a significant increase of 158.41% compared to the same period last year[5] - The basic and diluted earnings per share for Q3 2021 were both ¥0.33, reflecting a 94.12% increase year-over-year[9] - Total operating revenue for the first three quarters of 2021 reached ¥341,097,584.39, a 45.3% increase compared to ¥234,530,370.00 in the same period of 2020[37] - Net profit for the third quarter of 2021 was ¥86,949,842.52, compared to ¥51,885,173.34 in the same quarter of 2020, representing a 67.6% increase[39] - Basic earnings per share for the third quarter of 2021 were ¥1.42, up from ¥0.85 in the same quarter of 2020, indicating a 67.1% increase[42] - The total comprehensive income for the third quarter of 2021 was ¥86,949,842.52, compared to ¥51,885,173.34 in the same quarter of 2020, reflecting a 67.6% increase[42] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥1,016,403,557.08, marking a 164.10% increase from the end of the previous year[9] - The company's total assets as of September 30, 2021, were ¥1,016,403,557.08, compared to ¥384,855,194.54 at the end of 2020, marking an increase of about 164.5%[31] - Total liabilities increased to ¥245,817,987.18 from ¥191,936,883.15, which is an increase of approximately 28.0%[30] - Total liabilities amounted to ¥268,603,910.72, compared to ¥191,936,883.15 in the previous year, reflecting a 39.8% increase[37] - Current liabilities totaled 191,936,883.15, with accounts payable at 13,628,176.02 and contract liabilities at 128,292,304.80[54] Equity and Shareholder Information - The company's total equity attributable to shareholders increased to ¥741,418,402.25, a 292.07% rise from the previous year[9] - Total equity attributable to shareholders reached ¥741,418,402.25, significantly up from ¥189,104,685.80 in 2020, indicating a growth of 292.5%[37] - The number of common shareholders at the end of the reporting period was 80,000,000, with the largest shareholder holding 27.59% of the shares[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder owning 22,069,500 shares[18] Research and Development - The company's R&D expenditure for Q3 2021 was ¥15,901,438.13, which is a 121.01% increase compared to the same period last year[9] - The proportion of R&D expenditure to revenue for Q3 2021 was 13.59%, an increase of 4.47 percentage points year-over-year[9] - Research and development expenses for the first three quarters of 2021 totaled ¥35,676,542.07, compared to ¥19,935,145.21 in 2020, marking an increase of 78.9%[37] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥45,583,455.19, showing a slight decrease of 3.83% compared to the previous year[5] - Operating cash inflow for the first three quarters of 2021 was CNY 306,782,145.65, an increase of 28.1% compared to CNY 239,500,900.54 in the same period of 2020[46] - Cash outflow from operating activities totaled CNY 261,198,690.46, up 36.0% from CNY 192,101,184.75 year-on-year[46] - Cash inflow from investment activities was CNY 809,869.59, significantly lower than CNY 6,002,136.99 in the same period last year[49] - Cash outflow from investment activities surged to CNY 350,925,853.99, compared to CNY 66,052,490.99 in the previous year[49] - Net cash flow from financing activities was CNY 466,509,710.76, a substantial increase from a net outflow of CNY 2,785,689.40 in the same period last year[49] Other Financial Information - The company reported a financial expense of ¥1,212,540.52 for the third quarter of 2021, an increase from ¥830,809.45 in the same quarter of 2020[37] - The company’s investment income for the third quarter of 2021 was ¥567,205.55, compared to ¥2,136.99 in the same quarter of 2020[37] - The company has a long-term equity investment valued at ¥40,000,000.00 as of September 30, 2021[28] - The company implemented new leasing standards starting January 1, 2021, affecting the financial statements[57] - The company did not adjust comparative period information for the initial application of the new leasing standards[57]